1.
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
by Gueler, Aysel
AIDS (London), 2017, Vol.31 (3), p.427-436
2.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
by Fellay, Jacques
The Lancet (British edition), 2001, Vol.358 (9290), p.1322-1327
3.
Determinants of HIV-1 broadly neutralizing antibody induction
by Rusert, Peter
Nature medicine, 2016, Vol.22 (11), p.1260-1267
4.
Complete Genome Sequences of Two Swiss Hepatitis E Virus Isolates from Human Stool and Raw Pork Sausage
by Kubacki, Jakub
Genome announcements (Washington, DC), 2017, Vol.5 (35)
5.
High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study
by Schäfer, Juliane
AIDS care, 2017, Vol.29 (8), p.1056-1061
6.
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy
by Rohrbach, Janine
Gut, 2010, Vol.59 (9), p.1252-1258
7.
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
by Jaggy, Christian
The Lancet (British edition), 2003, Vol.362 (9387), p.877-878
8.
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy
by Young, Jim
Journal of clinical epidemiology, 2009, Vol.62 (6), p.632-641
9.
Trichinellosis in Immigrants in Switzerland
by LOZANO BECERA, Juan Carlos
Journal of travel medicine, 2012, Vol.19 (3), p.195-197
10.
Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
by Furrer, Hansjakob
The Lancet (British edition), 2000, Vol.355 (9222), p.2217-2218
11.
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV
by Kohler, Philipp
AIDS (London), 2015, Vol.29 (18), p.2509-2515
12.
Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study
by Osih, Regina B.
AIDS research and human retroviruses, 2010, Vol.26 (11), p.1239-1246
13.
A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study
by Walker, Timothy M
The Lancet infectious diseases, 2018, Vol.18 (4), p.431-440
14.
Adverse events of raltegravir and dolutegravir
by Elzi, Luigia
AIDS (London), 2017, Vol.31 (13), p.1853-1858
15.
HIV transmission under highly active antiretroviral therapy
by Vernazza, Pietro
The Lancet (British edition), 2008, Vol.372 (9652), p.1806-1807
16.
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infect...
by Huttner, Angela, Dr
The Lancet infectious diseases, 2017, Vol.17 (5), p.528-537
17.
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory S...
by Orasch, C
Clinical microbiology and infection, 2014, Vol.20 (7), p.698-705
18.
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
by YOUNG, Jim
AIDS (London), 2012, Vol.26 (5), p.567-575
19.
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality
by Glass, Tracy R
AIDS (London), 2015, Vol.29 (16), p.2195-2200
20.
Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting
by PURO, Vincenzo
European journal of epidemiology, 2004, Vol.19 (6), p.577-584
